Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score Matched Analysis

  • George Rodrigues*
  • , Cary Oberije
  • , Suresh Senan
  • , Kayoko Tsujino
  • , Terry Wiersma
  • , Marta Moreno-Jimenez
  • , Tae Hyun Kim
  • , Lawrence B. Marks
  • , Ramesh Rengan
  • , Luigi De Petris
  • , Sara Ramella
  • , Kim DeRuyck
  • , Nuria Rodriguez De Dios
  • , Andrew Warner
  • , Jeffrey D. Bradley
  • , David A. Palma
    • *Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score Matched Analysis'. Together they form a unique fingerprint.

Keyphrases

INIS

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science